



## Inhibition of DXR in the MEP Pathway with Lipophilic *N*-alkoxyaryl FR900098 Analogs

Darean Bague<sup>†,a</sup>, Ruiqin Wang<sup>†,a</sup>, Dana Hodge<sup>§</sup>, Marwa O. Mikati<sup>#</sup>, Jose S. Roma<sup>‡</sup>, Helena I. Boshoff<sup>‡</sup>, Allyson L. Dailey<sup>⊥</sup>, Misgina Girma<sup>⊥</sup>, Robin D. Couch<sup>⊥</sup>, Audrey R. Odom John<sup>#,§</sup>, and Cynthia S. Dowd<sup>\*,†</sup>


### Supplementary Information

Figure S1. IC <sub>50</sub> curves for <i>P. falciparum</i> Dxr inhibition	S2
Figure S2. IC <sub>50</sub> curves for <i>M. tuberculosis</i> Dxr inhibition	S6
Figure S3. IC <sub>50</sub> curves for wild-type and <i>had1</i> mutant <i>P. falciparum</i> inhibition	S7
Figure S4. Comparison charts for wild-type and <i>had1</i> mutant <i>P. falciparum</i> inhibition	S9


Figure S1. IC<sub>50</sub> curves for *P. falciparum* Dxr inhibition




Compound 6f




Compound 6j



Compound 6k



Compound 6l



### Compound 6n




Figure S2. IC<sub>50</sub> curves for *M. tuberculosis* Dxr inhibition






Figure S3. IC<sub>50</sub> curves for wild-type and *had1* mutant *P. falciparum* inhibition








Figure S4. Comparison charts for wild-type and *had1* mutant *P. falciparum* inhibition

